The FDA on June 17, 2026, approved Norwich Pharmaceuticals, Inc.’s abbreviated new drug application for generic baloxavir marboxil tablets, the first single-dose generic treatment for influenza. The product is the generic equivalent of Genentech’s Xofluza, indicated for treating acute uncomplicated influenza and for post-exposure prophylaxis in patients aged five years and older. According to the agency, the approval comes ahead of the 2026-2027 flu season and aligns with its Drug Competition Action Plan aimed at widening access to generics. FDA’s Iilun Murphy, M.D., described the approval as meaningful for improving both ease of use and access in a disease that affects millions annually.
The decision opens the influenza antiviral market to lower-cost competition within the single-dose segment for the first time. Xofluza had been distinguished by its ease of adherence compared with multi-dose treatments; a generic could shift market share quickly once distribution stabilizes. For payers and formulary managers, this approval signals coverage flexibility with a therapeutically equivalent option before the upcoming season. That may help lower per-course costs, while supporting adherence through simplified dosing. Pricing and exclusivity details weren’t included in the filing, though generics often reshape market pricing within months of launch.
Norwich’s timing could position it to meet early seasonal demand, especially in retail and public health channels looking to offset branded antiviral costs. Observers are likely to track whether additional manufacturers file their own ANDAs and how fast wholesalers move to add the product for flu season stocking. Employers and PBMs reviewing coverage tiers may start updating formularies in Q3 2026 as availability expands. For broader drug market context, see RxInfo.ai.